MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Adverum Biotechnologies Revenue 2011-2026 | ADVM
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Adverum Biotechnologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 M | 3.6 M | - | 7.5 M | - | 250 K | 1.61 M | 1.85 M | 1.46 M | 2.32 M | 572 K | 480 K | 30 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.5 M | 30 K | 1.88 M |
Quarterly Revenue Adverum Biotechnologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1 M | - | - | - | - | 3.6 M | - | - | - | - | 7.5 M | - | - | 7.5 M | - | - | - | - | - | 250 K | - | - | 70 K | 833 K | 493 K | 216 K | 461 K | 463 K | 463 K | 462 K | 488 K | 395 K | 307 K | 265 K | 960 K | 953 K | 203 K | 203 K | 203 K | 204 K | 135 K | 30 K | - | 30 K | 150 K | 300 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.5 M | 30 K | 1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M |  USA |
 |
AbbVie
ABBV
|
16.6 B | $ 232.08 | 3.29 % | $ 411 B | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.61 | 0.56 % | $ 1.08 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
3.5 M | $ 5.12 | -1.54 % | $ 109 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
18.1 M | $ 4.66 | -0.85 % | $ 773 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
958 M | $ 24.56 | -0.32 % | $ 4.07 B | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Achieve Life Sciences
ACHV
|
5.06 M | $ 4.56 | -3.59 % | $ 90.4 M | USA |
 |
AC Immune SA
ACIU
|
27.3 M | $ 2.93 | -1.01 % | $ 229 M |  Schweiz |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aclaris Therapeutics
ACRS
|
7.83 M | $ 2.87 | -8.31 % | $ 352 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
10.2 M | $ 2.96 | -4.67 % | $ 167 M | China |
 |
ADC Therapeutics SA
ADCT
|
2.34 M | $ 4.1 | -0.73 % | $ 105 M | Schweiz |
 |
ADMA Biologics
ADMA
|
510 M | $ 15.57 | 2.57 % | $ 3.71 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
277 M | $ 16.02 | -2.67 % | $ 2.43 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
ADiTx Therapeutics
ADTX
|
134 K | $ 0.46 | -4.63 % | $ 6.06 K | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Agenus
AGEN
|
156 M | $ 3.33 | -0.89 % | $ 1.19 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
54 M | $ 30.23 | 0.83 % | $ 1.75 B | USA |
 |
AIM ImmunoTech
AIM
|
141 K | $ 0.91 | -8.59 % | $ 43.8 M | USA |
 |
Akebia Therapeutics
AKBA
|
236 M | $ 1.31 | -0.76 % | $ 337 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Alector
ALEC
|
21 M | $ 2.43 | -5.08 % | $ 250 M | USA |
 |
Aligos Therapeutics
ALGS
|
6.19 M | $ 7.03 | -6.27 % | $ 452 M | USA |
 |
Alkermes plc
ALKS
|
1.48 B | $ 30.1 | -2.05 % | $ 4.96 B |  Irlanda |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Allogene Therapeutics
ALLO
|
95 K | $ 2.78 | 1.83 % | $ 436 M | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
3.71 B | $ 332.92 | 0.51 % | $ 43.6 B | USA |
 |
Altimmune
ALT
|
20 K | $ 4.31 | -3.36 % | $ 306 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
ALX Oncology Holdings
ALXO
|
1.18 M | $ 2.11 | -10.21 % | $ 110 M | USA |
 |
Amgen
AMGN
|
36.8 B | $ 388.16 | 2.33 % | $ 209 B | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |